Seres Therapeutics

Seres Therapeutics is a clinical-stage biotechnology company developing new therapies comprised of rationally selected live bacteria consortia, aiming to modulate the composition and function of the human microbiome to treat a wide range of diseases. Its team pioneered the development and FDA approval of the first-ever oral live biotherapeutic, VOWST, which was sold to Nestlé Health Science in September 2024. The company is based in Cambridge, United States.

Seres Therapeutics is a clinical-stage biotechnology company whose visionary team has been at the forefront of live biotherapeutics for over a decade. The company develops new therapies comprised of rationally selected live bacteria consortia, working to revolutionize treatment for a wide range of diseases by modulating the composition and function of the human microbiome. Its team pioneered the development and FDA approval of the first-ever oral live biotherapeutic, VOWST, which was sold to Nestlé Health Science in September 2024. Richard Kender serves as Executive Chair and Interim Chief Executive Officer; he has over 35 years of biopharma executive experience, including as Senior Vice President of Business Development and Corporate Licensing at Merck & Co., and has served on the Seres Board of Directors since 2014.

Pioneering live biotherapeutics for serious diseases

• VOWST

  The first-ever oral live biotherapeutic, developed and FDA-approved by the Seres team.

1. 1Establishing a Better Microbiome for Better Health - Seres Therapeuticsserestherapeutics.com
2. 2About Us - Seres Therapeuticsserestherapeutics.com
3. 3Seres Therapeutics (United States)wikidata.org